Abstract
Objective
To investigate the expressions of Galectin-3 (Gal-3), Bcl-2 and Bax in human pituitary adenomas, and to explore the interrelation among them.
Methods
RT-PCR and immunohistochemistry were applied to detect the mRNA and protein expressions of Gal-3, Bcl-2 and Bax in surgically excised human pituitary adenoma tissues, including invasive and non-invasive pituitary adenomas, and the correlation analysis was performed.
Results
The Gal-3 and Bcl-2 expressions in the invasive pituitary group were significantly higher than those in the non-invasive group, and the expression of Bax had no significant difference between the two groups. Pearson’s correlation analyses showed that the Gal-3 expression was positively correlated with Bcl-2, but was not correlated with Bax, which was inversely correlated with expression of Bcl-2.
Conclusion
Gal-3 may function through a cell death inhibition pathway involving Bcl-2 to enhance cell proliferation, which result in the invasive growth of pituitary adenoma. These results indicate that Gal-3 has an important role in pituitary tumor cell proliferation and may serves as a possible therapeutic target in treatment of pituitary tumors.
摘要
目的
探讨垂体腺瘤中半乳糖凝集素-3(Galectin-3, Gal-3)和凋亡相关基因 Bcl-2、 Bax 的内在联系。
方法
RT-PCR检测20例垂体腺瘤Gal-3、 Bcl-2和Bax mRNA的表达; 免疫组化染色检测78例垂体腺瘤中Gal-3、 Bcl-2和 Bax 蛋白表达, 分析侵袭性和非侵袭性垂体腺瘤中Gal-3、 Bcl-2 和Bax 表达的差异及其相关关系。
结果
侵袭组垂体腺瘤Gal-3和Bcl-2 mRNA和蛋白的表达水平较非侵袭组显著增高, 而Bax mRNA 和蛋白在两组中的表达水平无显著差异。 等级相关分析显示Gal-3 蛋白与Bcl-2 蛋白之间有正直线相关关系(r = 0.291, P = 0.01); Gal-3 蛋白与Bax蛋白之间无直线相关关系(r = −0.023, P > 0.05); Bcl-2 蛋白与Bax蛋白表达之间的Pearson相关系数为r = −0.267, P < 0.05(双侧), 呈负相关关系。
结论
Gal-3 可能主要是通过与Bcl-2 协同作用, 发挥其抗凋亡效应, 相对促进, 体腺瘤细胞增殖, 导致垂体腺瘤的侵袭性生长。这些结果提示Gal-3 在垂体肿瘤细胞增殖过程中发挥重要作用, 有望作为垂体腺瘤的一个治疗靶点。
Similar content being viewed by others
References
Liu FT, Patterson RJ, Wang JL. Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572: 263–273.
Nangia-Makker P, Honjo Y, Sarvis R, Akahani S, Hogan V, Pienta KJ, et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. Am J Pathol 2000, 156: 899–909.
Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852–6857.
Kawatani M, Imoto M. Deletion of the BH1 domain of Bcl-2 accelerates apoptosis by acting in a dominant negative fashion. J Biol Chem 2003, 278: 19732–19742.
Jaffrain-Rea ML, Di Stefano D, Minniti G, Esposito V, Bultrini A, Ferretti E, et al. A critical reappraisal of MIB-1 labelling index significance in a large series of pituitary tumours: secreting versus non-secreting adenomas. Endocr Relat Cancer 2002, 9:103–113.
Gong JY, Shi JX, Liu CJ, Hang CH, Cheng HL, Yin HX. The role of cell proliferating nuclear antigen on predicting the recurrence of postoperative pituitary adenomas. Chin J Neurosurg 2001, 17: 11–13.
Hardy J, Vezina JL. Transsphenoidal neurosurgery of intracranial neoplasm. Adv Neurol 1976, 15: 261–273.
Knosp E, Steiner E, Kitz K, Matula C. Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 1993, 33: 610–618.
Ochieng J, Fridman R, Nangia-Makker P, Kleiner DE, Liotta LA, Stetler-Stevenson WG, et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and-9. Biochemistry 1994, 33: 14109–14114.
Yu F, Finley RL Jr, Raz A, Kim HR. Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome C release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem 2002, 277: 15819–15827.
Raz A, Zhu DG, Hogan V, Shah N, Raz T, Karkash R, et al. Evidence for the role of 34-kDa galactoside-binding lectin in transformation and metastasis. Int J Cancer 1990, 46: 871–877.
Schoeppner HL, Raz A, Ho SB, Bresalier RS. Expression of an endogenous galactoside-binding lectin correlates with neoplastic progression in the colon. Cancer 1995, 75: 2818–2826.
Bresalier RS, Mazurek N, Sternberg LR, Byrd JC, Yunker CK, Nangia-Makker P, et al. Metastasis of human colon cancer is altered by modifying expression of the β-galactoside-binding protein galectin-3. Gastroenterology 1998, 115: 287–296.
Lotan R, Ito H, Yasui W, Yokozaki H, Lotan D, Tahara E. Expression of a 31 kDa lactose-binding lectin in normal human gastric mucosa and in primary and metastatic gastric carcinomas. Int J Cancer 1994, 56: 474–480.
van den Brûle FA, Engel J, Stetler-Stevenson WG, Liu FT, Sobel ME, Castronovo V. Genes involved in tumor invasion and metastasis are differentiall y modulated by estradiol and progestin in human breast cancer cells. Int J Cancer 1992, 52: 653–657.
Nangia-Makker P, Sarvis R, Visscher DW, Bailey-Penrod J, Raz A, Sarkar FH. Galectin-3 and L1 retrotransposons in human breast carcinomas. Breast Cancer Res Treat 1998, 49: 171–183.
Riss D, Jin L, Qian X, Bayliss J, Scheithauer BW, Young WF Jr, et al. Differential expression of galectin-3 in pituitary tumors. Cancer Res 2003, 63: 2251–2255.
Wang H, Wang MD, Ma WB, Yang D, Shi YF, Kong YG, et al. Expression of galectin-3 in invasive prolactinomas. Acta Academia Medicinae Sinica 2005, 27: 380–381.
Jin L, Riss D, Ruebel K, Kajita S, Scheithauer BW, Horvath E, et al. Galectin-3 expression in functioning and silent ACTH-producing adenomas. Endocr Pathol 2005, 16: 107–114.
Thodou E, Argyrakos T, Kontogeorgos G. Galectin-3 as a marker distinguishing functioning from silent corticotroph adenomas. Hormones (Athens) 2007, 6: 227–232.
Akahani S, Nangia-Makker P, Inohara H, Kim HR, Raz A. Galectin-3: a novel antiapoptotic molecule with a functional BH1 (NWGR) domain of Bcl-2 family. Cancer Res 1997, 57: 5272–5276.
Yoshii T, Fukumori T, Honjo Y, Inohara H, Kim HR, Raz A. Galectin-3 phosphorylation is required for its anti-apoptotic function and cell cycle arrest. J Biol Chem 2002, 277: 6852–6857.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Huang, CX., Hou, YH. & Liu, YS. Expression of galectin-3 correlates with apoptosis in pituitary adenoma cells. Neurosci. Bull. 24, 34–38 (2008). https://doi.org/10.1007/s12264-008-1029-y
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12264-008-1029-y